These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

110 related articles for article (PubMed ID: 12173280)

  • 61. Current and emerging treatments for mild/moderate acute ambulatory pain.
    Weaver AL
    Am J Ther; 2008; 15 Suppl 10():S12-6. PubMed ID: 19127123
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Current status of nonsteroidal anti-inflammatory drugs in physiatry: balancing risks and benefits in pain management.
    Kaplan RJ
    Am J Phys Med Rehabil; 2005 Nov; 84(11):885-94. PubMed ID: 16244527
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Direct medical costs of disease and gastrointestinal side effects during treatment for arthritis.
    Bloom BS
    Am J Med; 1988 Feb; 84(2A):20-4. PubMed ID: 3348239
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Assessment of coxib utilization by rheumatologists for nonsteroidal antiinflammatory drug gastroprotection prior to the coxib market withdrawals.
    Greenberg JD; Bingham CO; Abramson SB; Reed G; Kishimoto M; Hinkle K; Kremer J
    Arthritis Rheum; 2006 Aug; 55(4):543-50. PubMed ID: 16874798
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Clinical experience with cyclooxygenase-2 inhibitors.
    Lanas A
    Rheumatology (Oxford); 2002 Apr; 41 Supp 1():16-22; discussion 35-42. PubMed ID: 12173276
    [TBL] [Abstract][Full Text] [Related]  

  • 66. NSAID-associated adverse effects and acid control aids to prevent them: a review of current treatment options.
    Naesdal J; Brown K
    Drug Saf; 2006; 29(2):119-32. PubMed ID: 16454539
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Prevention and treatment of non-steroidal anti-inflammatory drug gastroenteropathy].
    Lanas A
    Rev Gastroenterol Mex; 2004; 69(4):251-60. PubMed ID: 15765979
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Gastrointestinal health care resource use and costs associated with nonsteroidal antiinflammatory drugs versus acetaminophen: retrospective cohort study of an elderly population.
    Rahme E; Joseph L; Kong SX; Watson DJ; LeLorier J
    Arthritis Rheum; 2000 Apr; 43(4):917-24. PubMed ID: 10765939
    [TBL] [Abstract][Full Text] [Related]  

  • 70. [The lack of awareness of the Israeli population regarding gastrointestinal complications from non-steroidal anti-inflammatory drugs].
    Zandman-Goddard G; Langevitz P
    Harefuah; 2001 Jun; 140(6):476-8, 567, 566. PubMed ID: 11420844
    [TBL] [Abstract][Full Text] [Related]  

  • 71. The iatrogenic costs of NSAID therapy: a population study.
    Sturkenboom MC; Romano F; Simon G; Correa-Leite ML; Villa M; Nicolosi A; Borgnolo G; Bianchi-Porro G; Mannino S
    Arthritis Rheum; 2002 Apr; 47(2):132-40. PubMed ID: 11954006
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Approaches to nonsteroidal anti-inflammatory drug use in the high-risk patient.
    Laine L
    Gastroenterology; 2001 Feb; 120(3):594-606. PubMed ID: 11179238
    [TBL] [Abstract][Full Text] [Related]  

  • 73. The economic consequences of NSAID-induced gastropathy: the French context.
    de Pouvourville G
    Scand J Rheumatol Suppl; 1992; 96():49-53. PubMed ID: 1439624
    [TBL] [Abstract][Full Text] [Related]  

  • 74. The economic consequences of NSAID-induced gastropathy in the United Kingdom and commentary on the article by G. de Pouvourville.
    Knill-Jones RP
    Scand J Rheumatol Suppl; 1992; 96():59-62. PubMed ID: 1439626
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Epidemiology and economics of NSAID-induced gastropathy.
    Zeidler H
    Scand J Rheumatol Suppl; 1992; 92():3-8. PubMed ID: 1574686
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Gastrointestinal side effects of NSAIDs - pharmacoeconomic implications.
    Sheen CL; MacDonald TM
    Expert Opin Pharmacother; 2002 Mar; 3(3):265-9. PubMed ID: 11866677
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Clinical economics review: gastrointestinal complications of non-steroidal anti-inflammatory drugs.
    Haslock I
    Aliment Pharmacol Ther; 1998 Feb; 12(2):127-33. PubMed ID: 9692686
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Economic comparison of nimesulide and diclofenac, and the incidence of adverse events in the treatment of rheumatic disease in Greece.
    Liaropoulos L
    Rheumatology (Oxford); 1999 May; 38 Suppl 1():39-46. PubMed ID: 10369405
    [TBL] [Abstract][Full Text] [Related]  

  • 79. NSAIDs and the gastrointestinal tract: an update on recent progress.
    Silverman GJ
    J Am Osteopath Assoc; 1999 Aug; 99(8 Suppl):S10-3. PubMed ID: 10732398
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Education-based approach to addressing non-evidence-based practice in preventing NSAID-associated gastrointestinal complications.
    Lanas A; Esplugues JV; Zapardiel J; Sobreviela E
    World J Gastroenterol; 2009 Dec; 15(47):5953-9. PubMed ID: 20014459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.